Milling and dry granulation of the halogenated diarylmethane API for direct compression tablets requires a pre-blend step that prevents segregation caused by the density difference between the aromatic bromide-chloride compound and microcrystalline cellulose. The active ingredient is first passed through an air jet mill to reduce the volume-median particle size to d90 ≤ 45 µm, with residual particles above 150 µm controlled at not more than 0.1% w/w because coarse fractions retard dissolution lag time in acidic media. The milled API is geometrically pre-blended with colloidal silicon dioxide at 0.5% w/w for 3 minutes at an API-to-filler ratio of 1:10, producing a free-flowing admixture suitable for bin blending. The primary filler system consists of microcrystalline cellulose PH102 and lactose monohydrate 200 M at a 1:1 to 2:1 ratio, with croscarmellose sodium incorporated at 2–5% w/w as an intragranular superdisintegrant. Blending proceeds in a 600 L bin blender at 12 rpm for 20 minutes, after which magnesium stearate is added at 0.5–0.75% w/w and mixed for a final 3 minutes. Extended magnesium stearate contact beyond 5 minutes increases the hydrophobic film on the API surface and reduces tablet tensile strength under compression. Compression is performed on a 16-station rotary tablet press with B-tooling, precompression force set at 2–4 kN, main compression force between 8 kN and 18 kN, and turret speed from 30 rpm to 60 rpm. Finished uncoated tablets are evaluated for hardness at 80–120 N, friability at not more than 1.0% w/w according to USP<1216>, and disintegration at not more than 15 minutes in 0.1 M HCl at 37 ± 0.5 °C according to USP<701>. Dissolution testing uses USP<711> paddle apparatus at 50 rpm with 900 mL of 0.1 M HCl containing 0.5% w/w sodium dodecyl sulfate, with sampling at 5, 10, 15, 30, 45, and 60 minutes. The terminal dosage form is a film-coated immediate-release tablet in 50 mg or 100 mg strengths, coated in a perforated pan with an aqueous dispersion of hypromellose 2910, titanium dioxide, and a plasticizer to a weight gain of 2–4% w/w.

What Limits Weight Uniformity When Filling Low-Density Halogenated Aromatic APIs into Hard Gelatin Capsules?

Weight uniformity faults in low-dose hard gelatin capsule filling of this halogenated diarylmethane are not primarily caused by the capsule shell but by the cohesive flow state of the micronized API. Milled material for capsule formulations often exhibits a bulk density of 0.25–0.40 g/mL and tapped density of 0.45–0.65 g/mL, placing the Carr index in the poor-flow range and requiring a flow aid at 0.5% w/w to reduce interparticulate cohesion. The fill formulation uses lactose monohydrate 200 M or mannitol pearlitol 160C as the primary filler, with pregelatinized starch at 5–15% w/w as a disintegrant and sodium stearyl fumarate at 0.5–1.0% w/w as the lubricant because magnesium stearate can delay dissolution from low-fill-weight capsules. Capsule filling is performed on a dosator-type machine with pin height adjusted to 4–6 mm and compression force set to produce powder plugs with a disintegration lag not exceeding 3 minutes when tested in 0.1 M HCl at 37 ± 0.5 °C. The filling environment is controlled at 45–55% RH and 25 °C because gelatin shells become brittle below 35% RH and soften above 65% RH. Weight uniformity is evaluated according to USP<905>, with acceptance value not more than 15.0 for content uniformity, and dissolution is tested by USP<711> paddle at 50 rpm in 900 mL of 0.1 M HCl with 0.5% w/w sodium dodecyl sulfate. The terminal product is a hard gelatin capsule in size 3 or 4, filled to 25 mg or 50 mg of API per capsule.

High-shear wet granulation of 4-Bromo-1-chloro-2-(4-ethoxybenzyl)benzene alters the poor flow profile of the micronized API by densifying primary particles into agglomerates with a target granule median size of 150–300 µm. A 10 L high-shear granulator is charged with the API, lactose monohydrate 200 M, microcrystalline cellulose PH102, and croscarmellose sodium at 2–5% w/w. The impeller runs at 300–600 rpm and the chopper at 1500–3000 rpm while a binder solution of povidone K30 at 3–5% w/w in purified water is added at 5–10 mL/min. Endpoint is determined by torque increase to 8–12 N·m or by power consumption reaching 40–60% of the granulator motor maximum. Overmassing beyond the torque plateau produces dense granules that resist tablet disintegration, while undermassing produces weak granules that collapse during fluid bed drying. The wet mass is passed through a conical mill fitted with a 1.0 mm screen at 1000 rpm, then dried in a fluid bed dryer with inlet air at 60–70 °C, product temperature at 35–45 °C, and inlet dew point below −20 °C. Drying continues until loss on drying is not more than 2.5% w/w. The dried granules are milled through a 0.8 mm screen, blended with extragranular croscarmellose sodium at 2–5% w/w, and lubricated with sodium stearyl fumarate at 0.5% w/w. Compression on a rotary press uses a main compression force of 12–18 kN to produce tablets with hardness 120–200 N, friability below 0.8% w/w, and disintegration not more than 15 minutes in 0.1 M HCl at 37 ± 0.5 °C. Residual solvent levels for the final granulated tablet must meet ICH Q3C limits for Class 2 and Class 3 solvents, and the granulation equipment train must be cleaned between batches according to 21 CFR 211 because the halogenated aromatic compound can adhere to stainless steel surfaces after drying.

Lyophilised Injection Matrix Design Cannot Ignore Collapse Temperature

Freeze-drying cycle design for the compound must begin with collapse temperature measurement by freeze-dry microscopy and differential scanning calorimetry because the eutectic or glass transition properties of the formulation matrix define the maximum shelf temperature during primary drying. The non-ionisable halogenated diarylmethane structure is expected to exhibit low aqueous solubility at neutral pH, so the formulation is prepared as a lyophilised cake from a water-miscible cosolvent or cyclodextrin-based solution. Published data for this specific configuration are limited; solubility screening in water–PEG 300–ethanol mixtures and in sulfobutylether β-cyclodextrin solutions is conducted before cycle development. The filling solution includes mannitol at 4–6% w/v or glycine at 1–2% w/v as the bulking agent, and the solution is filtered through a 0.22 µm PVDF membrane before filling into Type I glass vials. Freezing is performed at 0.5–1.0 °C/min to −40 °C, followed by annealing at −20 °C to −25 °C for 2–4 hours to promote complete crystallisation of the bulking agent. Primary drying is run at a shelf temperature of −20 °C to −10 °C and chamber pressure of 80–150 mTorr, with secondary drying at 40 °C for 4–6 hours. The terminal lyophilised cake must have residual moisture not more than 2% w/w by Karl Fischer titration according to USP<921>. Reconstitution time is measured with 5 mL of water for injection and should not exceed 60 seconds. Sterility is confirmed by USP<71>, bacterial endotoxins by USP<85> at not more than 0.5 EU/mg, and particulate matter by USP<788> with limits of not more than 6000 particles per container at ≥10 µm and not more than 600 particles per container at ≥25 µm. The finished product is a lyophilised powder for injection in 5 mL or 10 mL vials, intended for reconstitution with water for injection to an oral or parenteral dosage strength determined by the licensed monograph.

When Terminal Heat Sterilisation Is Replaced by Aseptic Filtration for Chlorinated Diarylmethane APIs

Thermal exposure at 121 °C for 15 minutes in a saturated steam autoclave may produce related substances from dehalogenation or oxidative degradation of the brominated and chlorinated aromatic rings, and a forced degradation study under ICH Q1A(R2) conditions is required before choosing the sterilisation route. If the related substances exceed 0.2% w/w under terminal heat sterilisation, aseptic filtration becomes the only acceptable processing route for the injectable solution. The compounding vessel is sterilised by dry heat at 250 °C for not less than 30 minutes, and the solution is prepared in water for injection with a co-solvent system determined by preformulation solubility data. The final bulk solution is filtered through a sterile 0.22 µm PVDF filter with a bacterial retention rating validated according to ASTM F838-20. Filter integrity is tested by bubble point or diffusion before and after filtration, with acceptance criteria based on the filter manufacturer’s minimum bubble point specification. The filtered solution is filled aseptically under ISO 5 conditions into depyrogenated Type I glass vials with nitrogen overlay to limit oxidative degradation of the halogenated aromatic core. The fill line uses a peristaltic or rotary piston pump with fill volume verification by gravimetric check weighing at 100% for the first 20 vials and periodically thereafter. The terminal injectable solution is inspected for visible particulates according to USP<790>, tested for particulate matter according to USP<788>, and released only after sterility by USP<71> and endotoxin by USP<85> with a limit of 0.5 EU/mg. The operational boundary is that the final solution must not contain reducing sugars or amine-based buffers because these components can react with chlorinated diarylmethane structures and compromise stability during storage.

For oral granular dose adjustment in paediatric and geriatric populations, the API is applied by fluid bed layering onto microcrystalline cellulose spheres using a Wurster column insert. The coating suspension contains the halogenated diarylmethane API dispersed with hypromellose 5 cP at 1–2% w/w solids in purified water, with polysorbate 80 at 0.02–0.05% w/w to reduce surface tension and improve wetting of the hydrophobic aromatic solid. The Wurster process operates at a product temperature of 40–50 °C, inlet air temperature of 60–70 °C, and atomising air pressure of 1.0–1.5 bar. Spray rate is adjusted to maintain a layering efficiency of at least 90% w/w, and the coated spheres are dried to not more than 2.0% w/w loss on drying. The final granules are blended with a flavour-masking agent and a flow aid, then filled into stick packs at 10 mg API per 1 g of granules. Uniformity of dosage units is confirmed by USP<905>, and dissolution is assessed by USP<711> paddle at 50 rpm in 900 mL of 0.1 M HCl with 0.5% w/w sodium dodecyl sulfate. The terminal finished product is an oral granule dosage form in stick packs that can be sprinkled onto soft food or dispersed in water immediately before administration.

Roller Compaction Ribbon Density and Milling Parameters for Halogenated Aromatic APIs Used in Immediate-Release Tablets

Ribbon density feedback in roller compaction for the halogenated diarylmethane must be continuously monitored because the brittle aromatic crystals densify under roll pressure but lose dissolution surface area if overcompacted. Dry granulation by roller compaction is used when the API is moisture-sensitive or when wet granulation solvents exceed ICH Q3C limits. The blend is fed into a laboratory roller compactor with 25 mm knurled rolls at a roll pressure of 50–80 kN, roll speed of 2–6 rpm, and gap control between 1.5 mm and 2.5 mm. Ribbon density is targeted between 0.8 g/cm³ and 1.1 g/cm³; ribbons below 0.8 g/cm³ produce excessive fines after milling, while ribbons above 1.1 g/cm³ reduce disintegration rate and prolong dissolution lag. The ribbons are milled through a conical mill with a 0.8 mm or 1.0 mm screen at 1000–1500 rpm, generating granules with d50 between 150 µm and 400 µm. The milled granulate is lubricated with sodium stearyl fumarate at 0.5% w/w and compressed on a rotary tablet press at 12–18 kN. Tablet hardness is measured at 100–180 N, friability is below 1.0% w/w per USP<1216>, and disintegration is not more than 15 minutes per USP<701>. Dissolution is run by USP<711> paddle at 50 rpm in 900 mL of 0.1 M HCl with 0.5% w/w sodium dodecyl sulfate. The operational boundary for this dry granulation route is the ribbon density window itself: below the lower limit, granule friability increases and the press die filling becomes unstable; above the upper limit, tablet disintegration times exceed the compendial limit and dissolution Q values fail at the 30-minute sampling point. The terminal product is a film-coated immediate-release tablet of 50 mg or 100 mg strength, with the dry granulation route selected only after confirming that the residual moisture of the final blend remains below 2.0% w/w during storage at 25 °C/60% RH for at least 24 months under ICH Q1A(R2) stability conditions.